Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.
about
MAO-inhibitors in Parkinson's DiseaseClinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson diseaseAssignment of genes for human monoamine oxidases A and B to the X chromosomeRasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase BThe central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitusThe neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in ratsMonoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illnessRecent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.Antidepressants and serotonergic neurotransmission: an integrative review.Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond.Rasagiline in treatment of Parkinson's disease.Platelet monoamine oxidase B: use and misuse.Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties.Selective inhibitors of monoamine oxidase (MAO-A and MAO-B) as probes of its catalytic site and mechanism.The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease.Electrophysiological effects of monoamine oxidase inhibition on rat midbrain dopaminergic neurones: an in vitro study.Effects of tranylcypromine stereoisomers on monamine oxidation in man.In vivo, noradrenaline is a substrate for rat brain monoamine oxidase A and B.L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors.Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex.limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30.Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.Neurotoxins and monoamine oxidase inhibition: new aspects.Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.
P2860
Q24629770-4BD04D76-34D9-4A77-88CF-3509B574C1D5Q28262497-79149B8C-1C99-4FAF-85B5-8673A0207E26Q28300194-9FF0CCBC-0ACC-4710-9599-C546F051F8FFQ28346410-5BB5FA5D-E582-46EF-B3C4-08542D2997A5Q31789217-8D186A04-553D-4E39-B7FD-247A496230A8Q34914164-70B56F69-2A66-43B4-A8BF-D1845ECE696DQ35545032-0A15238E-9244-4A4A-A8DA-61F571596D84Q35566604-364755CC-3B33-4E08-90A2-1439A6A70367Q36307876-6ABF739B-48EF-473F-BA10-DF66550AF788Q38151087-3D8FF111-80BD-410C-BAB2-420E78A55E6DQ38325601-35B159A0-CE8D-4E07-9649-1BE8C16E4118Q38447289-773DD5A4-3864-4132-BC00-BD612271D6EAQ39315311-B0E2E9F7-5243-4BF6-8670-9A94CC3A74A1Q39631444-55D97028-0D70-4E18-BB2E-F55240BF5026Q40182942-63410EF1-8B42-4B45-88E5-3A75623B9352Q40369097-4014FBAD-491B-4AC6-8385-F2C8535D973AQ40811619-CB6A505E-6162-4C62-B370-AB6A15AB5D88Q41829844-28EB5669-E214-4EA6-9353-8AD73664D6BEQ41962158-ED99CD39-12CB-43B8-B0C4-31E95EF98C85Q42248195-27C8D519-84FA-4AE7-9F37-590FF4FBD281Q42477440-0345D467-67F1-4C49-8327-5E9D827CD6AEQ42710523-008FA50B-EAF4-4874-BC47-F6132E7AD06EQ43247357-191FCEB4-57CE-4CE0-A3D2-E6BB7182BF73Q43442012-0228C975-016E-4031-8FA6-2AE5A36085AAQ44518976-AECFF596-BBAB-4874-A0CC-B24AC93C9623Q45010958-16883050-F4C4-4211-A260-8F27D5B037B4Q48352927-7F2559E7-5190-4F95-A20F-E435D59BEEA8Q48376744-7ABF7147-61FB-4881-A66E-EF1F64E28861Q48911414-710220F8-E1FD-4ECB-98D7-2DCBD552F837
P2860
Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Evidence for dopamine deaminat ...... amine and 5-hydroxytryptamine.
@en
type
label
Evidence for dopamine deaminat ...... amine and 5-hydroxytryptamine.
@en
prefLabel
Evidence for dopamine deaminat ...... amine and 5-hydroxytryptamine.
@en
P2093
P2860
P1476
Evidence for dopamine deaminat ...... amine and 5-hydroxytryptamine.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.1977.TB07506.X
P407
P577
1977-07-01T00:00:00Z